VSIG4 and colorectal carcinoma: In conclusion, our findings elucidate the key role of VSIG4+TAMs in modulating immune escape in CRC, suggesting that targeting macrophage VSIG4 could significantly improve the efficacy of anti‐PD‐1 therapy.